Pfizer Silences Testimony On Short-Term Prempro Use

Law360, New York (January 21, 2011, 7:38 PM EST) -- Plaintiffs in multidistrict litigation over Pfizer Inc.'s hormone replacement drug Prempro cannot present expert testimony that short-term use of the drug increases breast cancer risk, a judge has ruled on the eve of trial.

Dealing a blow to possibly hundreds of plaintiffs in the MDL, Judge William Wilson of the U.S. District Court for the Western District of Arkansas on Friday refused to reconsider a Wednesday order barring the testimony of the plaintiffs' expert epidemiologist, Dr. Donald Austin, from two cases set for trial Feb. 1....
To view the full article, register now.